linjc16/ctgov huggingface dataset:
Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy

Study Overview
=================
Brief Summary
-----------------
The medical records of 16 eyes of 16 patients with macular hole retinal detachment or myopic traction maculopathy who received viterctomy including internal limiting membrane peeling and scleral shorting surgery were reviewed. Best-corrected visual acuity, axial length, retinal reattachment and macular hole closure, the shape of staphyloma determined by optical coherence tomography and 3-dimensional magnetic resonance imaging were assessed.

Official Title
-----------------
Efficacy of Surgical Treatment of Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy

Conditions
-----------------
Macular Hole Retinal Detachment, Myopic Traction Maculopathy

Intervention / Treatment
-----------------
* Procedure: Vitrectomy with scleral shortening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria were patients who had highly myopic eyes with macular hole retinal detachment to myopic traction maculopathy Exclusion Criteria: The patients with follow-up less than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Vitrectomy with scleral shortening|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity before and after surgery | Comparison with logarithm of Minimum Angle of Resolution (logMAR) vision | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal reattachment | Retinal reattachment or resolution of myopic traction maculopathy | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myopic traction maculopathy
Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
The objective is to assess the efficacy of Hepatitis B Virus vaccination in a population of IBD patients treated with immunosuppressive medications.

Official Title
-----------------
Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases

Conditions
-----------------
Inflammatory Bowel Disease

Intervention / Treatment
-----------------
* Biological: ENGERIX-B (HBV Vaccine)
* Biological: Sci-B-Vac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/female ≥ 18 years of age Evidence of IBD as diagnosed by clinical, laboratory imaging and endoscopic criteria. Treated with at least one immunosuppressive medication at the time of study initiation Provided written informed consent. Exclusion Criteria: Pregnant women Diagnosis of chronic viral hepatitis B Any major acute medical event in the 30 days prior to recruitment that necessitated hospitalization ( acute myocardial infarction, CVA, pulmonary emboli, sepsis, major trauma) Any other chronic inflammatory condition not related to IBD ( connective tissue disease, Chronic liver disease, COPD, poorly controlled diabetes mellitus) Active hematologic or oncologic diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ENGERIX-B<br> | Biological: ENGERIX-B (HBV Vaccine)<br>* ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.<br>* Other names: ENGERIX-B;|
| Experimental: Sci-B-Vac<br> | Biological: Sci-B-Vac<br>* Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| protective level of anti HBs antibodies | Antibody titer >10 IU/ml 30 days following last vaccine dose will be considered protective. In the work done by Altunoz et al., titer rate below 10 IU was observed in 40% of the patients, while 40% of the patients achieved a rate of above 100 IU. Therefore, we can estimate that the geometric mean of distribution is approx. 50 IU. A sample size of 37 patients in each group achieves a power of 80% to detect a ratio above 1.37 between the two vaccinated groups. | 1 month after the last does of vaccine | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HBV, Inflammatory bowel disease, immunosuppressor
Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study

Study Overview
=================
Brief Summary
-----------------
Prospective cohort study evaluating the role of leptin receptors in the bariatric surgical population compared with non obese controls. Additionally serum levels of leptin, ghrelin, motilin and PYY will be compared amongst the different BMI classes and a quality of life questionnaire completed by all participants. The hypothesis is that obese individuals have lower leptin receptors in enterocytes which is partially responsible for the higher serum leptin levels without appropriate control of satiety.

Official Title
-----------------
Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Endoscopic Intervention Exclusion Criteria: 18 years of age or older No acute GI bleeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1: Control Group<br>BMI <30 There are 20 controls in this group | |
| Group 2<br>BMI 30-35 There were 12 controls in this class | |
| Group 3<br>BMI 35-40 There were 9 controls in this clas | |
| Group 4<br>BMI >40 There were 9 controls in this class | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PCR test for Leptin Receptors | Endoscopic biopsies of enterocytes will be measured via PCR | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ELISA test for ghrelin, motilin, leptin and PYY | Blood samples collected to determine hormones via ELISA | 1 week | 
| IWQOL lite questionnaire | Quality of Life questionnaire on obesity | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Leptin
Use of Tamoxifen in Systemic Mastocytosis

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard non-cytotoxic medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.

Detailed Description
-----------------
Not desired

Official Title
-----------------
Treatment of Systemic Mastocytosis With Tamoxifen

Conditions
-----------------
Systemic Mastocytosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systemic Mastocytosis Exclusion Criteria: Current treatment with Imatinib mesylate, cladribine or interferon alpha.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stability or reduction of the percent bone marrow involvement by mastocytosis, including stable mast cell morphology and phenotype. | up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard non-cytotoxic medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40mg/day and the duration of treatment will be for one year. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stability or improvement in biochemical markers of systemic mastocytosis | Stability or improvement in biochemical markers of systemic mastocytosis (serum tryptase, calcitonin, urinary N-methyl histamine and prostaglandin F2 excretion/24 hours, liver function studies, lactic dehydrogenase, complete blood count with leukocyte differential) | 1 year |
Internet Delivered CBT for Body Dysmorphic Disorder

Study Overview
=================
Brief Summary
-----------------
To evaluate if Internet delivered cognitive behavior therapy is an efficacious treatment when compared to a control group consisting of supportive therapy.

Official Title
-----------------
Internet Delivered Cognitive Behavior Therapy for Body Dysmorphic Disorder - a Randomized Controlled Trial

Conditions
-----------------
BDD, Body Dysmorphic Disorder

Intervention / Treatment
-----------------
* Behavioral: Cognitive behavior therapy
* Behavioral: Supportive therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: outpatient ≥ 18 years primary diagnosis of BDD according to the DSM-5 BDD-YBOCS ≥20 regular access to a computer with Internet access and skills to use the web. Exclusion Criteria: psychotropic medication changes within two months prior to the treatment, completed CBT for BDD within the last 12 months, other primary axis I diagnosis current substance dependence lifetime bipolar disorder or psychosis suicidal ideation Axis II diagnosis that could jeopardize treatment participation, other current psychological treatment that could affect BDD symptoms A serious medical illness that precludes participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cognitive behavior therapy<br> | Behavioral: Cognitive behavior therapy<br> <br> |
| Active Comparator: Supportive therapy<br> | Behavioral: Supportive therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Dysmorphic Disorder Modification of the Y-BOCS (BDD-YBOCS) |  | Change in BDD-YBOCS from baseline (week 0) to post-treatment (week 12) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Montgomery Åsberg Depression Rating Scale - self report (MADRS-S) |  | Change in MADRS-S from baseline (week 0) to post-treatment (week 12) |
Anaerobic Antibiotic Usage for Pneumonia in the Medical Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
Observation of prescription usage of anaerobic antibiotics for patients admitted to the ICU with pneumonia.

Detailed Description
-----------------
Pneumonia is a common admitting diagnosis in the intensive care unit (ICU). When aspiration is suspected, antibiotics to cover anaerobes are frequently used , but in the absence of clear risk factors, current guidelines have questioned their role. It is unknown how frequently these guidelines are followed.

Official Title
-----------------
Anaerobic Antibiotic Usage for Pneumonia in the Medical Intensive Care Unit

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Drug: Antibiotics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU patients with diagnosis of pneumonia Exclusion Criteria: patients with abdominal infections such as c diff.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antibiotics|Observation of antibiotic types given to patients with pneumonia.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usage of anaerobic antibiotics | Percent of patients receiving inappropriate anaerobic antibiotics | 6 months |
Rigid Versus Flexible Cystoscopy in Women

Study Overview
=================
Brief Summary
-----------------
The study will help define the best tolerated approach to cystoscopy in women by randomly comparing flexible to rigid cystoscopy. Previous randomized studies evaluated rigid cystoscopy under general anesthesia versus flexible cystoscopy under local anesthesia. As a result of these studies, flexible cystoscopy is performed in the clinic setting generally in males. However, many women have rigid cystoscopy performed in the clinic while the men have flexible cystoscopy. No studies to date have evaluated whether flexible cystoscopy is better tolerated in women compared to rigid cystoscopy in women in the clinic setting.

Official Title
-----------------
Rigid Versus Flexible Cystoscopy in Women in Outpatient Clinic

Conditions
-----------------
Hematuria, Urination Disorders, Voiding Dysfunction, Recurrent Urinary Tract Infection

Intervention / Treatment
-----------------
* Device: Flexible Cystoscopy
* Device: Rigid Cystoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Exclusion Criteria: Minors Incarcerated individuals

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Flexible Cystoscopy<br>Flexible Cystoscopy | Device: Flexible Cystoscopy<br> <br> |
| Active Comparator: Rigid Cystoscopy<br>Rigid Cystoscopy | Device: Rigid Cystoscopy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analog Scale for Pain | The Visual Analog Scale for pain ranges from 1 to 5, with higher scores indicating higher pain. Results report the average of two measures, taken during procedure and 1 week post-procedure. | During procedure and 1 week post-procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bladder cancer surveillance, Voiding dysfunction, Cystoscopy
Changes of Pressure on Soft Tissue Before and After Total Hip Replacement to Prevent Bedsores

Study Overview
=================
Brief Summary
-----------------
Patients candidates for total hip replacement are, generally elderlies and have hip pain, we will check if the pressure to the soft tissue changes before and after operation using a tapet with pressure sensors sending the information to specific software.

Detailed Description
-----------------
one hundred Patients 60 years old and more will be considered for this study, both sexs, that have schedule for elective unilateral total hip replacement and have not bedsores previously. All the data will be collected by FSA software, classified in an excel table. A crossover study will be performed and analyzed by a paired test.

Official Title
-----------------
Changes of Pressure on Soft Tissue Before and After Total Hip Replacement to Prevent Bedsores

Conditions
-----------------
Transient Arthropathy of Hip

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 60 y/o/ and more Both sexes Schedule for total hip replacement Exclusion Criteria: Patient with previous bedsore Patients under 60 y.0. Previous CVA

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pressure of total hip replacement<br>Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in soft tissue pressure | Mapping of pressure will be performed twice for each patient' the first one before surgery the second one before discharge. The measure will be performed by resting, normal position | Day one | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hip, Bedsores, pressure
Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy and safety of the addition of intravaginal isosorbide mononitrate to an established protocol of oral misoprostol for cervical ripening and labor induction.

Official Title
-----------------
Randomized Clinical Trial of Cervical Ripening and Labor Induction Using Stepwise Oral Misoprostol With or Without Intravaginal Isosorbide Mononitrate

Conditions
-----------------
Cervical Ripening

Intervention / Treatment
-----------------
* Drug: Misoprostol with or without isosorbide mononitrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:: Pregnant women 18 years of age or greater Singleton pregnancy between 32-42 weeks gestation requiring labor induction Membranes must be intact Exclusion Criteria: Ruptured membranes Gestational age less than 32 weeks Non-reassuring fetal heart rate tracing

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Misoprostol<br> | Drug: Misoprostol with or without isosorbide mononitrate<br>* Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed<br>|
| Active Comparator: Misoprostol with Isosorbide Mononitrate<br> | Drug: Misoprostol with or without isosorbide mononitrate<br>* Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to vaginal delivery |  | First dose of study medication to delivery |